Feasibility of onchocerciasis elimination with ivermectin treatment in endemic foci in Africa: first evidence from studies in Mali and Senegal

Lamine Diawara, Mamadou O Traoré, Alioune Badji, Yiriba Bissan, Konimba Doumbia, Soula F Goita, Lassana Konaté, Kalifa Mounkoro, Moussa D Sarr, Amadou F Seck, Laurent Toé, Seyni Tourée, Jan H F Remme, Lamine Diawara, Mamadou O Traoré, Alioune Badji, Yiriba Bissan, Konimba Doumbia, Soula F Goita, Lassana Konaté, Kalifa Mounkoro, Moussa D Sarr, Amadou F Seck, Laurent Toé, Seyni Tourée, Jan H F Remme

Abstract

Background: Mass treatment with ivermectin is a proven strategy for controlling onchocerciasis as a public health problem, but it is not known if it can also interrupt transmission and eliminate the parasite in endemic foci in Africa where vectors are highly efficient. A longitudinal study was undertaken in three hyperendemic foci in Mali and Senegal with 15 to 17 years of annual or six-monthly ivermectin treatment in order to assess residual levels of infection and transmission and test whether ivermectin treatment could be safely stopped in the study areas.

Methodology/principal findings: Skin snip surveys were undertaken in 126 villages, and 17,801 people were examined. The prevalence of microfilaridermia was <1% in all three foci. A total of 157,500 blackflies were collected and analyzed for the presence of Onchocerca volvulus larvae using a specific DNA probe, and vector infectivity rates were all below 0.5 infective flies per 1,000 flies. Except for a subsection of one focus, all infection and transmission indicators were below postulated thresholds for elimination. Treatment was therefore stopped in test areas of 5 to 8 villages in each focus. Evaluations 16 to 22 months after the last treatment in the test areas involved examination of 2,283 people using the skin snip method and a DEC patch test, and analysis of 123,000 black flies. No infected persons and no infected blackflies were detected in the test areas, and vector infectivity rates in other catching points were <0.2 infective flies per 1,000.

Conclusion/significance: This study has provided the first empirical evidence that elimination of onchocerciasis with ivermectin treatment is feasible in some endemic foci in Africa. Although further studies are needed to determine to what extent these findings can be extrapolated to other endemic areas in Africa, the principle of elimination has been established. The African Programme for Onchocerciasis Control has adopted an additional objective to assess progress towards elimination endpoints in all onchocerciasis control projects and to guide countries on cessation of treatment where feasible.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1. Location of the three study…
Figure 1. Location of the three study areas in Mali and Senegal.
Figure 2. Prevalence of onchocerciasis infection in…
Figure 2. Prevalence of onchocerciasis infection in the R. Gambia focus.
Figure 3. Prevalence of onchocerciasis infection in…
Figure 3. Prevalence of onchocerciasis infection in the R. Bakoye focus.
Figure 4. Prevalence of onchocerciasis infection in…
Figure 4. Prevalence of onchocerciasis infection in the R. Faleme focus.
Figure 5. Study design and study phases…
Figure 5. Study design and study phases in each study site.
Figure 6. Vector infectivity rates in the…
Figure 6. Vector infectivity rates in the three study areas after 15 to 17 years of ivermectin treatment.
Figure 7. Vector infectivity rates and prevalence…
Figure 7. Vector infectivity rates and prevalence of infection 16 to 22 months after the last treatment in the test area in the R. Gambia focus.
Figure 8. Vector infectivity rates and prevalence…
Figure 8. Vector infectivity rates and prevalence of infection 16 to 22 months after the last treatment in the test area in the R. Bakoye focus.
Figure 9. Vector infectivity rates and prevalence…
Figure 9. Vector infectivity rates and prevalence of infection 16 to 22 months after the last treatment in the test area in the R. Faleme focus.

References

    1. World Health Organization. Onchocerciasis and its control. Report of a WHO Expert Committee on Onchocerciasis Control. World Health Organ Tech Rep Ser. 1995;852:1–104.
    1. Boatin B. The Onchocerciasis Control Programme in West Africa (OCP). Ann Trop Med Parasitol. 2008;102(Suppl 1):13–17.
    1. Remme JHF, Feenstra P, Lever PR, Medici AC, Morel CM, et al. Tropical diseases targeted for elimination: Chagas disease, lymphatic filariasis, onchocerciasis and leprosy. In: Jamison DT, Breman JG, Measham AR, editors. Disease Control Priorities in Developing Countries, second edition. New York: Oxford University Press; 2006. pp. 433–449.
    1. Thylefors B. The Mectizan Donation Program (MDP). Ann Trop Med Parasitol. 2008;102(Suppl 1):39–44.
    1. Amazigo U. The African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2008;102(Suppl 1):19–22.
    1. Sauerbrey M. The Onchocerciasis Elimination Program for the Americas (OEPA). Ann Trop Med Parasitol. 2008;102(Suppl 1):25–29.
    1. Abiose A, Jones BR, Cousens SN, Murdoch I, Cassels-Brown A, et al. Reduction in incidence of optic nerve disease with annual ivermectin to control onchocerciasis. Lancet. 1993;341:130–134.
    1. Cousens S, Cassels-Brown A, Murdoch I, Babalola O, Jatau D, et al. Impact of annual dosing with ivermectin on progression of onchocercal visual field loss. Bull World Health Organ. 1997;75:229–236.
    1. Brieger WR, Awedoba AK, Eneanya CI, Hagan M, Ogbuagu KF, et al. The effects of ivermectin on onchocercal skin disease and severe itching: results of a multicentre trial. Trop Med Int Health. 1998;3:951–961.
    1. Basáñez MG, Pion SDS, Boakes E, Filipe JAN, Churcher TS, et al. Effect of single-dose ivermectin on Onchocerca volvulus: a systematic review and meta-analysis. Lancet Infect Dis. 2008;8:310–322.
    1. Remme J, De Sole G, Dadzie KY, Alley ES, Baker RH, et al. Large scale ivermectin distribution and its epidemiological consequences. Acta Leiden. 1990;59:177–191.
    1. Committee of Sponsoring Agencies. African Programme for Onchocerciasis Control: programme document. Washington DC: World Bank; 1996.
    1. Sékétéli A, Adeoye G, Eyamba A, Nnoruka E, Drameh P, et al. The achievements and challenges of the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96:15–28.
    1. Amazigo UV, Obono M, Dadzie KY, Remme J, Jiya J, et al. Monitoring community-directed treatment programmes for sustainability: lessons from the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96(Suppl 1):S75–92.
    1. Plaisier AP, Alley ES, Boatin BA, Van Oortmarssen GJ, Remme H, et al. Irreversible effects of ivermectin on adult parasites in onchocerciasis patients in the Onchocerciasis Control Programme in West Africa. J Infect Dis. 1995;172:204–210.
    1. Winnen M, Plaisier AP, Alley ES, Nagelkerke NJ, van Oortmarssen G, et al. Can ivermectin mass treatments eliminate onchocerciasis in Africa? Bull World Health Organ. 2002;80:384–391.
    1. Bottomley C, Isham V, Collins RC, Basáñez MG. Rates of microfilarial production by Onchocerca volvulus are not cumulatively reduced by multiple ivermectin treatments. Parasitology. 2008;135:1571–1581.
    1. Dadzie Y, Neira M, Hopkins D. Final report of the conference on the eradicability of onchocerciasis. Filaria J. 2003;2:2.
    1. WHO. Criteria for certification of interruption of transmission/elimination of human onchocerciasis. Geneva: World Health Organization; 2001. 64
    1. Boatin BA, Hougard JM, Alley ES, Akpoboua LK, Yaméogo L, et al. The impact of Mectizan on the transmission of onchocerciasis. Ann Trop Med Parasitol. 1998;92(Suppl 1):S46–60.
    1. Borsboom GJ, Boatin BA, Nagelkerke NJ, Agoua H, Akpoboua KL, et al. Impact of ivermectin on onchocerciasis transmission: assessing the empirical evidence that repeated ivermectin mass treatments may lead to elimination/eradication in West-Africa. Filaria J. 2003;2:8.
    1. Prost A, Hervouet JP, Thylefors B. The degrees of endemicity of onchocerciasis. Bull World Health Organ. 1979;57:655–662.
    1. World Health Organization. Strategies for ivermectin distribution through primary health care systems. Geneva: World Health Organization; 1991. WHO/PBL/91.24.
    1. Remme J, Ba O, Dadzie KY, Karam M. A force-of-infection model for onchocerciasis and its applications in the epidemiological evaluation of the Onchocerciasis Control Programme in the Volta River basin area. Bull World Health Organ. 1986;64:667–681.
    1. De Sole G, Baker R, Dadzie KY, Giese J, Guillet P, et al. Onchocerciasis distribution and severity in five West African countries. Bull World Health Organ. 1991;69:689–698.
    1. De Sole G, Giese J, Keita FM, Remme J. Detailed epidemiological mapping of three onchocerciasis foci in West Africa. Acta-Trop. 1991;48:203–213 issn: 0001–0706x.
    1. Baker RH, Guillet P, Sékétéli A, Poudiougo P, Boakye D, et al. Progress in controlling the reinvasion of windborne vectors into the western area of the Onchocerciasis Control Programme in West Africa. Philos Trans R Soc Lond B Biol Sci. 1990;328:731–747, discussion 747–750.
    1. Bissan Y, Hougard JM, Doucoure K, Akpoboua A, Back C, et al. Drastic reduction of populations of Simulium sirbanum (Diptera: Simuliidae) in central Sierra Leone after 5 years of larviciding operations by the Onchocerciasis Control Programme. Ann Trop Med Parasitol. 1995;89:63–72.
    1. Boakye DA. A pictorial guide to the chromosomal identification of members of the Simulium damnosum Theobald complex in west Africa with particular reference to the Onchocerciasis Control Programme Area. Trop Med Parasitol. 1993;44:223–244.
    1. Boakye DA, Back C, Fiasorgbor GK, Sib AP, Coulibaly Y. Sibling species distributions of the Simulium damnosum complex in the west African Onchocerciasis Control Programme area during the decade 1984–93, following intensive larviciding since 1974. Med Vet Entomol. 1998;12:345–358.
    1. De Sole G, Remme J, Awadzi K, Accorsi S, Alley ES, et al. Adverse reactions after large-scale treatment of onchocerciasis with ivermectin: combined results from eight community trials. Bull World Health Organ. 1989;67:707–719.
    1. World Health Organization. Epidemiology of onchocerciasis. Technical Report Ser World Health Organ. 1976;597:94.
    1. Prost A, Prod'hon J. [Parasitological diagnosis of onchocerciasis. A critical review of present methods (author's transl)]. Med Trop Mars. 1978;38:519–532.
    1. Boatin BA, Toé L, Alley ES, Nagelkerke NJ, Borsboom G, et al. Detection of Onchocerca volvulus infection in low prevalence areas: a comparison of three diagnostic methods. Parasitology. 2002;125:545–552.
    1. Toé L, Back C, Adjami AG, Tang JM, Unnasch TR. Onchocerca volvulus: comparison of field collection methods for the preservation of parasite and vector samples for PCR analysis. Bull World Health Organ. 1997;75:443–447.
    1. Unnasch TR, Meredith SE. The use of degenerate primers in conjunction with strain and species oligonucleotides to classify Onchocerca volvulus. Methods Mol Biol. 1996;50:293–303.
    1. Katholi CR, Toé L, Merriweather A, Unnasch TR. Determining the prevalence of Onchocerca volvulus infection in vector populations by polymerase chain reaction screening of pools of black flies. J Infect Dis. 1995;172:1414–1417.
    1. Remme JH. Research for control: the onchocerciasis experience. Trop Med Int Health. 2004;9:243–254.
    1. Agoua H, Alley ES, Hougard JM, Akpoboua KL, Boatin B, et al. Etudes entomologiques de post-traitement dans le Programme de Lutte contre l'Onchocercose en Afrique de l'Ouest. Parasite. 1995;2:281–288.
    1. Plaisier AP, van Oortmarssen GJ, Remme J, Alley ES, Habbema JD. The risk and dynamics of onchocerciasis recrudescence after cessation of vector control. Bull World Health Organ. 1991;69:169–178.
    1. Remme JHF, Alley ES, Plaisier AP. Estimation and prediction in tropical disease control: the example of onchocerciasis. In: Mollison D, editor. Epidemic models: their structure and relation to data. Cambridge: Cambridge University Press; 1995. pp. 372–392.
    1. Hougard JM, Alley ES, Yaméogo L, Dadzie KY, Boatin BA. Eliminating onchocerciasis after 14 years of vector control: a proved strategy. J Infect Dis. 2001;184:497–503.
    1. World Health Organization. Report of the nineteenth session of the Joint Programme Committee of the Onchocerciasis Control Programme in West Africa. World Health Organ; 1998. 42
    1. Yaméogo L, Toe L, Hougard JM, Boatin BA, Unnasch TR. Pool screen polymerase chain reaction for estimating the prevalence of Onchocerca volvulus infection in Simulium damnosum sensu lato: results of a field trial in an area subject to successful vector control. Am J Trop Med Hyg. 1999;60:124–128.
    1. World Health Organization. Onchocerciasis Control Programme in West Africa - Progress Report of the World Health Organization for 2000. Geneva: 2000. 40
    1. Remme J, Baker RH, De Sole G, Dadzie KY, Walsh JF, et al. A community trial of ivermectin in the onchocerciasis focus of Asubende, Ghana. I. Effect on the microfilarial reservoir and the transmission of Onchocerca volvulus. Trop Med Parasitol. 1989;40:367–374.
    1. Trpis M, Childs JE, Fryauff DJ, Greene BM, Williams PN, et al. Effect of mass treatment of a human population with ivermectin on transmission of Onchocerca volvulus by Simulium yahense in Liberia, West Africa. Am J Trop Med Hyg. 1990;42:148–156.
    1. Cupp EW, Ochoa JO, Collins RC, Cupp MS, Gonzales-Peralta C, et al. The effects of repetitive community-wide ivermectin treatment on transmission of Onchocerca volvulus in Guatemala. Am J Trop Med Hyg. 1992;47:170–180.
    1. Boussinesq M, Prod'hon J, Chippaux J. Onchocerca volvulus: striking decrease in transmission in the Vina valley (Cameroon) after eight annual large scale ivermectin treatments. Trans R Soc Trop Med Hyg. 1997;91:82–86.
    1. Basáñez MG, Remme JH, Alley ES, Bain O, Shelley AJ, et al. Density-dependent processes in the transmission of human onchocerciasis: relationship between the numbers of microfilariae ingested and successful larval development in the simuliid vector. Parasitology. 1995;110:409–427.
    1. Mafuyai HB, Post RJ, Vajime CG, Molyneux DH. Cytotaxonomic identifications of the Simulium damnosum complex (Diptera:Simuliidae) from Nigeria. Trop Med Int Health. 1996;1:779–785.
    1. Soumbey-Alley E, Basáñez MG, Bissan Y, Boatin BA, Remme JH, et al. Uptake of Onchocerca volvulus (Nematoda: Onchocercidae) by Simulium (Diptera: Simuliidae) is not strongly dependent on the density of skin microfilariae in the human host. J Med Entomol. 2004;41:83–94.
    1. Quillévéré D. Contribution a l'étude des caractéristiques taxonomiques, bioécologiques et vectrices des membres du complexe Simulium damnosum presents en Côte d'Ivoire. Travaux et documents de LÓRSTOM, no 109. Paris: ORSTOM; 1979. 304
    1. Noma M, Nwoke BE, Nutall I, Tambala PA, Enyong P, et al. Rapid epidemiological mapping of onchocerciasis (REMO): its application by the African Programme for Onchocerciasis Control (APOC). Ann Trop Med Parasitol. 2002;96(Suppl 1):S29–39.
    1. African Programme for Onchocerciasis Control. Addendum to Plan of Action and Budget 2008–2015. Ouagadougou: World Health Organization; 2008. 31

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe